28-30 January 2019
Paris, France
3 Passes Remaining. Book Now!



Imke Mulder
Director of Research
4D Pharma

Day Two

Wednesday 30 January 2019

09.15 | Developing Live Biotherapeutics to Target Immuno-Oncology

Travis Whitfill
Chief Scientific Officer

Travis Whitfill is the Chief Science Officer of Azitra Inc. His background began in molecular biology and biochemistry after receiving scientific training at the MD Anderson Cancer Center and Duke University. He has co-founded several biotech and healthcare startups companies, including Azitra. Mr. Whitfill’s strong background in entrepreneurship and business was recently acknowledged when he was named one of Forbes’ 30 Under 30 in 2018. He serves as a partner at Bios Partners, a healthcare-focused venture capital fund based in Texas, and as the Senior Analyst at Bios Research, which provides research services to institutional investors. He also is an Associate Research Scientist in the Department of Pediatrics at Yale University. Mr. Whitfill received degrees from Yale University (MPH) and Dallas Baptist University (BS in biology).

Assaf Oron
Chief Business Officer

Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity.  At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.

Day Two

Wednesday 30 January 2019

10.40 | Utilising Phage to Improve Immuno-Oncology Therapy

Adrien Nivoliez
Chief Executive Officer
Biose industrie

As Chief Executive Officer at biose® industrie, Adrien currently manages the GMP pharmaceutical Contract Development & Manufacturing Organization (CDMO) for Live Biotherapeutic Products.

Jeffrey Heiser
Director of Microbiology
Boston Analytical

Jeffrey Heiser is a cGMP pharmaceutical microbiology testing expert that has spent time in industry in cell culture manufacturing contamination response, rapid micro method evaluations and multivalent vaccine testing design and validation.  Jeff directs the Microbiology side of Boston Analytical’s contract lab service where he implements both routine and non-routine testing programs.  Most recently, Jeff has been heading up the QC program design and implementation for Boston Analytical’s Microbiome client base.

Day Two

Wednesday 30 January 2019

09.35 | Application of Multivalent Vaccine Manufacturing Testing Schemes in cGMP Characterisation of Microbiome Defined Drug Products

Luc Sterkman
Chief Executive Officer
Caelus Health

Luc Sterkman, MD obtained his medical degree (MD) in 1988 at the Free University, Amsterdam. He has broad experience in the fields of general management, BD and R&D. From 1992-2002 he was COO and later CEO of U-Gene Research, a European CRO, which was sold to Kendle USA. From 2002 to 2010, he was Board member of the biotech company OctoPlus and later GM at the pharmaceutical company Disphar International, part of the Nordic Group. From 2011-2016 he was COO at Newtricious, a company focusing on innovative nutrition and functional foods. As CEO at Caelus Health, he is since January 2016 responsible for directing the company in the next phase of growth and further expanding its pipeline of new microbiota-based products in the field of cardio-metabolic diseases.

Arne Materna
VP, Product

Day One

Tuesday 29 January 2019

10.00 | Shotgun Sequencing & Strain-Level Analysis: Study Design for Pre-Clinical & Clinical Development

Julia Cope
Director of Scientific Operations

Dr. Julia Cope is a microbiologist and plant pathologist with training in bioinformatics, and statistics. Her postdoctoral training included work in human microbiome projects for both research and clinical trials at the Texas Children’s Microbiome Center of Texas Children’s Hospital. She currently works with Diversigen, Inc. as the Director of Scientific Operations spearheading pre-clinical and clinical projects in the Microbiome on Human and Animal Health. She has extensive experience in microbiome study design, handling of various sample types, multiple sequencing platforms and the underlying bioinformatics analysis.

Day One

Tuesday 29 January 2019

09.00 | Identification of Microbiome-Based Biomarkers and Challenges Associated with Their Application: Case Studies from Obesity, IBD, and Cancer

James Mcilroy
Founder & Chief Business Officer

Dr James McIlroy is a part-time NHS Doctor and the Founder of EnteroBiotix, a biotechnology company that is building on the proven science of faecal microbiota transplantation (FMT) to develop novel medicines that target gut-dwelling bacteria to serve patients with serious unmet clinical needs. He holds an Honours degree in Physiology from the University of Edinburgh and a degree in Medicine (MBChB) from the University of Aberdeen, graduating with a distinction and the Elective Prize in Child Health. After graduating, James was appointed as an Honorary Lecturer in Healthcare Innovation to The School of Medicine, Medical Sciences and Nutrition. He started EnteroBiotix as a medical student and built the company alongside his studies - raising over £2m of investment, hosting a visit from the First Minister for Scotland and securing several major NHS partnerships. Under his leadership, the company became the first in the world to secure a license from the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbial products derived from faecal donations. His main research interest is the role and influence of gut bacteria in the pathogenesis and management of intestinal and extra-intestinal disease. He has presented published serval peer-reviewed articles and book chapter in journals such as Frontline Gastroenterology, Alimentary Pharmacology and Therapeutics and Advances in Experimental Medicine and Biology.

Alexandre Almeida
Postdoctoral Research Fellow
European Bioinformatics Institute

Kristin Wannerberger
Director of Partnerships
Ferring Pharmaceuticals

Jim Brown
Director of Computational Biology & Senior Fellow,

Responsible for the managing bioinformatics for: 1) Oncology Therapeutic Area including immuno-oncology; 2) Infectious Disease Therapeutic Area Unit including antivirals, antibacterials & host defense; 3) Diseases of the Developing World including TB, malaria and kinetoplastid therapeutics and; 4) Microbiome Collaborative Network which is leading the application of human microbiome studies to drug discovery. Elected as GSK Senior R&D Fellow in 2016.

Daniel van der Lelie
Chief Scientific Officer
Gusto Global

Dr. Daniel van der Lelie is the Chief Scientific Officer and Co-Founder of Gusto Global, a leading microbiome drug discovery and development company focused on the rational design of live biotherapeutics that modulate the immune system.  Dr. van der Lelie has worked in senior management roles in biotechnology, agriculture, environmental sciences and on the interface between biological sciences and nanotechnology throughout his career.  Prior to founding Gusto Global, he was the Global Director of Ag BioSolutions R&D at FMC Corporation.   Dr. van der Lelie’s position at FMC resulted from the company’s acquisition of the Center for Agriculture and Environmental Biotechnology, a business unit founded by Dr. van der Lelie at Research Triangle Institute. Prior to FMC and RTI, Dr. van der Lelie was the founder of the microbiology group and the co-founder of the group for bioinspired assembly of nanomaterials at Brookhaven National Laboratory. Dr. van der Lelie’s research has resulted in more than 150 publications in peer reviewed journals, including PLoS ONE, PLoS Genetics, Nature, Nature Chemistry, Nature Nanotechnology and Nature Biotechnology, and 21 patents / patent applications.

James Kinross
Senior Lecturer and Consultant in Colorectal Surgery
Imperial College London

Pr Laurence Zitvogel
Group Leader of Tumour Immunology & Immunotherapy of Cancer
Institut Gustave Roussy

Pr L. Zitvogel, MD (clinical oncology), PhD (tumor immunology), PU-PH Faculty Paris Sud, University Paris XI (Clinical Biology), graduated in Medical Oncology from the School of Medicine of the University of Paris in 1992. She started her scientific career when she was at the University of Pittsburgh in the USA in Michael Lotze’s laboratory. She became Research Director at Institut National de la Santé et Recherche Médicale U1015, and Scientific Director of the Immuno-Oncology programmm at Gustave Roussy, the largest cancer Center in Europe. She has been actively contributing to the field of cancer immunology and immunotherapy, and she brought together basic and translational research, including the design of cancer therapies through combined animal studies and Phase I/II patient trials. Her expertise is mainly dendritic cell and innate effector biology and relevance during tumour development as well as exosome-based vaccine designs. She pioneered the concept of immunogenic cell death and showed that chemotherapy, radiotherapy and inhibitors of tyrosine kinase mediate their tumoricidal activity, at least partly through the immune system. Her team discovered the critical role and impact of gut microbiota in cancer immunosurveillance and therapies. She was the recipient of many awards including the National Academy of Medicine, the Translation Research INSERM Prize, the ASCO-SITC, the Brupbacher Awards 2017 and the ESMO Immuno-Oncology Award 2017.

Day Two

Wednesday 30 January 2019

08.30 | The Impact of the Intestinal Microbiota in Therapeutic Responses Against Cancer

Alexander Sulakvelidze
EVP & Chief Scientist

Dr. Alexander “Sandro” Sulakvelidze, Ph.D., is an Executive Vice-President and Chief Scientific Officer of Intralytix, Inc.  Dr. Sulakvelidze is an internationally recognized expert in phage technology and infectious disease epidemiology.  He has published extensively on the subjects of phage biocontrol and phage therapy, and he is the author of several issued and pending patents in the field of bacteriophages.  Dr. Sulakvelidze also co-edited a major book about bacteriophages, which was published by the CRC Press in 2005.

Ling- Yang Hao
Principal Scientist
Janssen Pharmaceuticals

Pr Lars Engstrand
Department of Microbiology, Tumor and Cell Biology
Karolinska Institutet

Professor Lars Engstrand has more than 30 years experience as a clinical microbiologist. His research interest includes the pathophysiology, diagnosis and treatment of gastrointestinal infections and studies on cellular interactions and pathogenesis particularly in the context of Helicobacter pylori infections. In a number of studies, population-based epidemiology has been combined with clinical and basic microbiological science, including molecular biology and genomics. Similar approaches have been applied on studies of the human microbiome in health and disease where he initiated the use of next generation sequencing technology in studies of the human gut microbiome. Cross-departmental collaborations have been developed with a number research centers in Europe and the US. He is Director of the Clinical Genomics facility and the Centre for Translational Microbiome Research at Science for Life Laboratory/Karolinska Institute in Stockholm.

Day One

Tuesday 29 January 2019

08.30 | Definition of a Healthy Microbiome and if Disturbed - How to Shape It Back to Normal

Georges Rawadi
Chief Executive Officer
LNC Therapeutics

Formerly researcher at Institut Pasteur, Georges was Vice President of Business Development & Intellectual Property and a member of the management team at Celyad. Previously, he successfully held various business development positions at Cellectis, Galapagos, ProStrakan and Sanofi-Aventis and led strategic alliance development consulting assignments. He holds a Ph.D. in Microbiology from Pierre and Marie Curie University (France) and a Master’sdegree in Management and Strategy in the Health Industry from ESSEC Business School.

Day One

Tuesday 29 January 2019

17.30 | Novel Therapeutic Approaches Targeting the Microbiome in Metabolic Diseases

Hassan Benameur
Senior Director & President

Dr. Hassan Benameur is Senior Director Oral Drug Delivery Innovation, Global Pharma Biotech R&D at Lonza, with over 20 years of expertise in advanced drug delivery development. Dr. Benameur provides expertise in novel polymer applications for drug delivery and optimized lipid-based formulations for enhanced absorption to maximize success and reduce attrition in pharmaceutical product development.

Day One

Tuesday 29 January 2019

17.50 | Pioneering the Microbiome Oral Delivery for First-in-Man Studies

Tina Christensen Ram
Head of Quality
Luina Bio

Emilie Plantamura
Clincal Project Manager
MaaT Pharma

Herve Affagard
Chief Executive Officer
MaaT Pharma

As an entrepreneur in residence, Hervé has led MaaT Pharma since its inception phase in 2014. Notably, he was awarded Entrepreneur of the Year in Healthcare (2016) in recognition of his outstanding contribution to the development of MaaT Pharma.

Cheryl Zimberlin
Merck Ventures

Benjamin Hadida
Chief Executive Officer

Benjamin Hadida co-founded Nextbiotix in December 2016 and has served as Chief Executive Officer since.  Benjamin is an entrepreneur who developed a wide range of competences in various industries : investment banking (UBS), venture capital (Pacific Channel), pharmaceutical regulatory affairs (Amgen), biotech operations (Theravectys), applied research (Vision Institute in Paris). Benjamin has a Master in Management from ESSEC Business School and a Master in Molecular and Cellular Biology from Pierre and Marie Curie University (UPMC - Sorbonne University).

Mike Romanos,
Chief Executive Officer

Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities. In his last role he led a trans-national group of 300 staff providing genomics, target and biomarker discovery, and platform biology for R&D.

Trevor Lawley
Chief Scientific Officer

Trevor Lawley is a co-founder and Chief Scientific Officer of Microbiotica. He is also Faculty Group Leader of the Host-Microbiota Interactions Team at the Wellcome Trust Sanger Institute (WTSI), where his research uses advanced metagenomic sequencing and deep culturing to investigate the microbial communities contained on and within host organisms that are associated with health and a range of diseases and syndromes such as infections, autoimmunity, irritable bowel syndromes and cancer. He has pioneered many aspects of the bacteriotherapy concept where defined mixtures of bacteria are used to cure intestinal diseases linked to pathological imbalances in the intestinal microbiota.

Herwig Bachmann
Expertise Group Leader Fermentation

Magali Cordaillat-Simmons
Scientific and Regulatory Affairs Director
Pharmabiotic Research Institute

Magali Cordaillat-Simmons earned her PhD in 2005 at Université Descartes - Paris, France, in Cardiovascular Pharmacology. She then worked as a Research Associate at the University of Virginia, VA, USA, where she studied the influence of epigenetics on renin expression. Today, she is the Executive Director for Scientific & Regulatory Affairs at the Pharmabiotic Research Institute (PRI), located in France. The PRI is Europe’s first and only expert regulatory group dedicated to supporting its members in the development and market authorization of Microbiotic Medicinal Products (MMPs). As a non-profit, Pro-industry organization, the PRI is uniquely positioned to both be a trusted point of contact for the European regulatory authorities, as well as an agile and neutral partner for the Microbiome & Health industries. Dr. Cordaillat-Simmons currently supervises the Association’s analysis of the European Pharmaceutical Legislation as well as the PRI’s unique regulatory intelligence strategy so that “Microbiotic Medicinal Products” may become a therapeutic reality for European patients.

Day Two

Wednesday 30 January 2019

14.00 | Overcoming Regulatory Challenges for Microbiome-Based Therapeutics

Massimo Marzorati
Chief Executive Officer

Massimo Marzorati graduated in 2003 from the University of Milan (Italy) in Biotechnology. In 2007 he obtained a PhD degree in the field of microbial ecology at the University of Milan. In 2007 he started as a post-doctoral researcher at LabMET, Ghent University (Belgium). His main research interest is the interaction between intestinal bacteria and human health. This includes pro- and prebiotics, microbial metabolism and bioavailability of food compounds and pharmaceuticals and the relation between the structure of the intestinal microbiota and its resilience under changing environmental conditions. In 2008, he founded ProDigest, a spin-off company from Ghent University, which provides customized services in the field of gastrointestinal transit, bioavailability and metabolism, to the operators in the food, feed and pharmaceutical industry.

Ryan Wilson
Head of Live-Bio Programmes
Quay Pharma

Nicholas Monsul
Chief Executive Officer
Quorum Innovations

Dr. Monsul was born in Philadelphia and graduated from Drexel University.  He completed his medical training at Drexel University College of Medicine, Yale University School of Medicine and The Johns Hopkins Hospital.  Throughout his career and education, he has been involved in basic science research.  He is a surgeon with a busy practice in the Hawthorne Clinic and Research Center and a Co-Founder & CEO of Quorum Innovations, LLC where he with Co-Founder Dr. Eva Berkes were recently awarded their seventh patent by the USPTO in drug discovery in the microbiome research.

Day One

Tuesday 29 January 2019

17.10 | Establishing the Role of Biofilms in Human Microbiome Discovery

Esther Aarts
Associate PI - Donders Centre for Cognitive Neuroimaging
Radboud University

Ken Blount
Chief Scientific Officer

Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.

Pr Mohamed Mohty MD
Professor of Hematology and Head of Hematology Department
Saint-Antoine Hospital and University Pierre & Marie Curie

Mohamad Mohty is Professor of Hematology and head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France). Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. Before moving to Paris, he was head of the Transplant Program at the University-Hospital of Nantes, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK. Professor Mohty’s translational research activity is focused on the pathophysiology of graft-vs-host disease and the immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as IMiDs and hypomethylating agents. He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of multiple myeloma. Professor Mohty is chairman of the Acute Leukemia Working Party (ALWP) and president-elect of the European Group for Blood and Marrow Transplantation (EBMT). He serves on the board of the EBMT, and the “Intergroupe Francophone du Myelome” (IFM). He is a member of the American Society of Hematology, American Society for Clinical Oncology, American Society for Blood and Marrow Transplantation, European Hematology Association, International Society for Experimental Hematology, and EBMT. Professor Mohty has published more than 210 peer-reviewed articles in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals. He also serves as an Associate Editor for Leukemia, Bone Marrow Transplantation, European Journal of Haematology and Blood Cancer Journal, as a member of the editorial board of Haematologica, and as a regular reviewer in different immunology, hematology, and cancer journals such as Blood and The Lancet.

Jeanette Mucha
Co-Founder and CEO,

Jeanette is a microbiologist and immunologist with over fourteen years experience. She is a prolific inventor who holds patents in the areas of microbial strain selection and immunology, as well as numerous provisional patents and trade secrets. She has a BS in Biology from the University of Miami. Jeanette is also a 18 time Ironman distance triathlon finisher, including the 2009 World Championship.

David Cook
Chief Scientific Officer
Seres Therapeutics

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres. He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.

Henry Rath
SVP Corporate Development
Seres Therapeutics

Denise Kelly
Investment Advisor
Seventure Partners

Denise joined Seventure Partners in September 2015 as a Consultant in the Life Sciences team for the microbiome field. Denise is currently based in Aberdeen, Scotland. As specialist in research on the human microbiome, she is responsible for relationships within the scientific and academic communities on behalf of Seventure Partners, identifying new investment opportunities in the field specific to the microbiome. Denise received a BSc and a PhD from Queen’s University in Belfast. She is Professor Emeritus of the University of Aberdeen

Jessica Schneider
Associate Scientific Director

Gregory Lambert

Pr Ernst Holler
Department of Hematology and Oncology
University Clinic Regensburg

James Chalmers
School of Medicine
University of Dundee

Pr Sahar Aidy
Groningen Biomolecular Sciences and Biotechnology Institute
University of Groningen

Bruce Roberts
Chief Scientific Officer
Vedanta Biosciences

Dr. Roberts has 30 years of experience in biotechnology and pharmaceutical drug discovery and development. He most recently served as Head of Neuro-Immunology and Immune-Mediated Disease Research at Sanofi Genzyme where he directed pre-clinical efforts resulting in the introduction of therapeutic antibodies, gene therapies, cell therapies and small molecules into multiple clinical trials for the treatment of cancer, multiple sclerosis and autoimmunity. He also directed research efforts in support of several approved products including lemtrada, aubagio, thymoglobulin, Mozobil, alemtuzumab, leukine, chlofarabine and fludarabine and contributed to the generation of ecallantide. Dr. Roberts has authored more than 50 peer-reviewed publications and contributed to several issued patents and patent applications. He received his PhD. in Biochemistry from the University of Ottawa, Canada.

Day Two

Wednesday 30 January 2019

10.20 | Advancing Cancer Immunotherapy Candidates Based on Microbiome-Derived LBPs that Stimulate the Immune System

Pr Martin Kriegel MD
Department of Immunobiology and Rheumatology
Yale University

Dr. Kriegel is an Assistant Professor of Immunobiology and of Medicine (Rheumatology) at Yale School of Medicine. In 2001, he received his MD/PhD equivalent at the Friedrich-Alexander University of Erlangen, Germany, followed by the German Medical Licensure in 2002. From 2003 to 2006, he performed postdoctoral training in immunology at Yale with Dr. Richard Flavell before completing a medicine residency and rheumatology fellowship at Harvard (Beth Israel Deaconess Medical Center and Brigham & Women’s Hospital). During this time, he performed additional postdoctoral research at Harvard Medical School with Drs. Diane Mathis and Christophe Benoist. Dr. Kriegel returned to Yale in 2012 as a tenure-track faculty member in the Department of Immunobiology. He is also a board-certified rheumatologist at Yale-New Haven Hospital and maintains a specialty clinic for antiphospholipid syndrome. His NIH-funded laboratory explores host-microbiota interactions in immune diseases by combining human microbiome studies with mechanistic work, which includes utilization of gnotobiotic models. He was an Emmy-Noether Scholar of the German Research Foundation, an Arthritis National Research Foundation Scholar, an awardee of the Lupus Research Institute, and the Arthritis Foundation. He serves as an Advisory Editor for Arthritis & Rheumatology and is a member of the American Association for the Advancement of Science, the German and American Association of Immunologists, the American College of Rheumatology, and the Society for Mucosal Immunology.

Day One

Tuesday 29 January 2019

09.30 | Investigating the Causal Role of the Microbiota in Immune- Mediated Diseases

Thomas Kuri
Scientific Director
Zymo Research